Navigation Links
Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2012 Results; Teleconference and Webcast to be held on November 15, 2011
Date:11/15/2011

CRANBURY, N.J., Nov. 15, 2011 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE Amex: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, today announced results for its first quarter ended September 30, 2011. Palatin reported a net loss of $3.4 million, or $(0.10) per basic and diluted share, for the quarter ended September 30, 2011, compared to a net loss of $4.6 million, or $(0.39) per basic and diluted share, for the same period in 2010.

The decrease in net loss for the quarter ended September 30, 2011, compared to the same period last fiscal year, is the result of Palatin's previously announced strategic decision to reduce staffing levels and to focus resources and efforts on clinical trials of bremelanotide and preclinical development of an inhaled formula of PL-3994 and a new peptide drug candidate for sexual dysfunction.  The decrease in net loss per share was also significantly impacted by the higher number of shares outstanding in the quarter ended September 30, 2011 compared to the same period last fiscal year due primarily to the sale of shares of stock in March 2011.

REVENUERevenues for the quarter ended September 30, 2011 were $27,000, compared to $216,000 for the same period in 2010, reflecting the decrease in revenue recognized under Palatin's agreements with AstraZeneca AB.

COSTS AND EXPENSESTotal operating expenses for the quarter ended September 30, 2011 were $3.4 million, compared to $4.8 million for the comparable quarter of 2010. The decrease in operating expenses for the quarter is the result of Palatin's previously announced strategic decision to reduce staffing levels and to focus resources and efforts on clinical trials of bremelanotide and PL-3994 and preclinical development of an inhaled formul
'/>"/>

SOURCE Palatin Technologies, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Palatin Technologies, Inc. Reports Positive Results of Phase 2a Clinical Study with PL-3994 for the Treatment of Heart Failure
2. Palatin Technologies, Inc. Revised Call-In Number for Teleconference and Webcast to be held on September 30, 2008
3. Palatin Technologies to Report Fiscal Year 2009 First Quarter Results; Conference Call and Webcast on November 17, 2008
4. Palatin Technologies Receives Notification Letter from NYSE Alternext US
5. Palatin Technologies to Report Fiscal Year 2009 Second Quarter Results; Conference Call and Webcast on February 17, 2009
6. Palatin Technologies Listing Compliance Plan Accepted by NYSE Alternext US
7. Palatin Technologies, Inc. Receives U.S. Patent Allowance for Heart Failure Drug Candidate
8. Palatin Technologies, Inc. Reports Positive Bremelanotide Study; Improved Safety Profile with Subcutaneous Administration
9. Palatin Technologies, Inc. to Raise $3.1 Million in Registered Direct Offering
10. Palatin Technologies to Present at the Rodman & Renshaw 11th Annual Global Investment Conference
11. Palatin Technologies, Inc. to Report Fourth Quarter and Fiscal Year 2009 Results; Teleconference and Webcast to be held on September 8, 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 15, 2014 Freeslate, Inc ... solutions, today announced that Lupin Limited, one of ... of Freeslate’s CM Protégé PharmD System ... Lupin, headquartered in Mumbai, India, is focused on ... branded formulations and Active Pharmaceutical Ingredients (APIs) for ...
(Date:1/14/2014)... San Diego, CA (PRWEB) January 14, 2014 ... developing solutions based on the products of cells ... they have entered into an international license agreement ... containing Histogen’s proprietary multipotent cell conditioned media (CCM). ... to the existing license between Histogen and Suneva ...
(Date:1/14/2014)... and BETHESDA, Md. , Jan. ... are joining together with two institutes from the ... develop more reliable tools for bringing safer, more ... Organovo is collaborating with the National Center for ... Institute (NEI) to develop better and more clinically ...
(Date:1/14/2014)... , Jan. 14, 2014   Kinaxis ®, ... management ( SCM ) and sales and operations planning ... gold sponsor of the Biomanufacturing Summit , which ... January 30 – 31, 2014.  At the conference, join ... Chain at Amgen, as she presents ,Supply Chain: Improving ...
Breaking Biology Technology:Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 3Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 2Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 3Organovo Announces Collaboration with National Institutes of Health 2Organovo Announces Collaboration with National Institutes of Health 3Event Alert: Kinaxis Customer to Present at the Biomanufacturing Summit "Supply Chain: Improving Network Effectiveness" 2
... Scientific,Corporation (NYSE: BSX ) is scheduled to participate ... being held September 10 and 11,in New York City. ... make a,25-minute presentation followed by a 25-minute question and ... a.m. ET. A live webcast of Mr. LaViolette,s ...
... Artery ... Disease - ... -, FREMONT, Calif., Aug. 28 Vermillion, Inc.,(Nasdaq: VRML ), formerly ... called beta-2,microglobulin may aid in the diagnosis of peripheral artery disease (PAD).,The findings, ...
... (Pink Sheets: BIEL), announced today that Astonix Life,Science, ... provide ActiPatch,Therapy to the healthcare market in Singapore. ... ActiPatch to the market has been warmly,received. ... the Healthcare providers,in Singapore has been strong enough ...
Cached Biology Technology:Vermillion and Collaborators Discover Protein Biomarker Associated with Peripheral Artery Disease 2Vermillion and Collaborators Discover Protein Biomarker Associated with Peripheral Artery Disease 3BioElectronics Corporation Announces Singapore and Malaysia Sales 2
(Date:4/14/2014)... of subarctic forest moths in Finnish Lapland suggests that ... on animals and plants because much of the harm ... of 80 moth species and found that 90 percent ... study period, from 1978 to 2009. During that time, ... degrees Fahrenheit, and winter precipitation increased as well. , ...
(Date:4/14/2014)... climate over the past three decades have caused small ... national animal. UCLA biologists have found that not only ... has also become shorter and higher pitched. ... integrative biology and physiology and of ecology and evolutionary ... study examined 170 male coqui frogs ( Eleutherodactylus coqui ...
(Date:4/14/2014)... ( http://www.ucr.edu ) David Kisailus, the Winston ... University of California, Riverside,s Bourns College of Engineering, ... Fellows are young scientists selected by the advisory ... National Academy of Sciences and organizers of the ... series. The Kavli Foundation, which is based in ...
Breaking Biology News(10 mins):Moth study suggests hidden climate change impacts 2Moth study suggests hidden climate change impacts 3Climate change a likely culprit in coqui frog's altered calls, say UCLA biologists 2Professor receives young scientist honor 2
... permanently damaged their skin cells, causing them to overproduce ... uneven skin tone over time. But new research indicates ... arthritis ?can actually help stop the formation of new ... findings on glucosamine may impact the way dermatologists treat ...
... warm, sun-drenched, tropical seas; some species are found at ... waters throughout the world's oceans. Some cold-water coral reefs ... a diversity rivaling some better known tropical coral reefs. ... method in which vessels drag large, heavily weighted nets ...
... the rewarding effect of cocaine on mice by genetically ... animal's brain. , While the researchers aren't suggesting that ... brings to light the key protein that controls cocaine's ... medications that achieve the same results and therefore help ...
Cached Biology News:Science finds new fix for UV-damaged skin in arthritis treatment 2Science finds new fix for UV-damaged skin in arthritis treatment 3Ocean acidification threatens cold-water coral ecosystems 2Genetically altered mice no longer like cocaine 2Genetically altered mice no longer like cocaine 3
Human Apolipoprotein B100 Affinity Purified Polyclonal Ab ENTREZ GeneID: 338...
hypertension-related calcium-regulated gene, mRNA...
Human PLUNC MAb (Clone 252512)...
... GRASP1 ( Abpromise for all ... Synthetic peptide corresponding to amino ... region of rat GRASP1, conjugated to ... Entrez GeneID: 56850 ...
Biology Products: